Literature DB >> 23234803

Genetic polymorphisms in the Fas and FasL genes are associated with epithelial ovarian cancer risk and clinical outcomes.

Yan Li1, Ya-li Hao, Shan Kang, Rong-miao Zhou, Na Wang, Bing-li Qi.   

Abstract

AIM: In this study, we evaluated whether functional polymorphisms within the Fas and FasL genes were associated with the risk of developing epithelial ovarian cancer (EOC) and survival of patients with EOC.
METHODS: A case-control study was performed in 342 EOC patients and 344 control women. The genotypes of three promoter region polymorphisms (Fas -1377G/A, -670A/G and FasL -844T/C) were determined using ligase detection reaction-polymerase chain reaction (LDR-PCR). The clinical outcomes in 202 EOC patients were compared across genotypes.
RESULTS: The genotype frequencies of the FasL -844 T/C polymorphism were significantly different between the case and control groups (P=0.034). Compared to the T/T and T/C genotypes, the C/C genotype significantly increased the risk of developing EOC (OR=1.46, 95% CI=1.08-1.99). The survival analysis showed that the Fas -1377G/A and -670A/G polymorphisms were related to prognosis in EOC patients. Compared with patients with the G/G genotype of the -1377G/A polymorphism, patients carrying the A allele had a shorter PFS and OS, as determined by univariate and multivariate analysis (HR=1.81, 95% CI=1.26-2.62 and HR=1.86, 95% CI=1.15-3.00, respectively). Similarly, Kaplan-Meier and Cox proportional hazard model analyses indicated that patients carrying the G allele of Fas -670A/G polymorphisms had shorter PFS and OS than those carrying the AA genotype (HR=1.67, 95% CI=1.15-2.42 and HR=1.80, 95% CI=1.10-2.94, respectively).
CONCLUSIONS: Functional polymorphisms in the Fas and FasL genes may be involved in epithelial ovarian cancer development and progression in northern Chinese women.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23234803     DOI: 10.1016/j.ygyno.2012.12.002

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Association of FAS A-670G Polymorphism and Risk of Uterine Leiomyoma in a Southeast Iranian Population.

Authors:  Abbas Mohammadpour-Gharehbagh; Saeedeh Salimi; Farshid Keshavarzi; Sepideh Zakerian; Mojtaba Sajadian; Mojgan Mokhtari
Journal:  Rep Biochem Mol Biol       Date:  2016-10

2.  Significant association among the Fas -670 A/G (rs1800682) polymorphism and esophageal cancer, hepatocellular carcinoma, and prostate cancer susceptibility: a meta-analysis.

Authors:  Tao Liu; Li Zuo; Lin Li; Lei Yin; Kai Liang; Hongyuan Yu; Hui Ren; Wen Zhou; Hongwei Jing; Yang Liu; Chuize Kong
Journal:  Tumour Biol       Date:  2014-08-02

3.  The VDR gene FokI polymorphism and ovarian cancer risk.

Authors:  Hui Xu; Su Li; Jian-Qing Qiu; Xiao-Lin Gao; Ping Zhang; Yong-Xia Yang
Journal:  Tumour Biol       Date:  2013-12

4.  Promoter polymorphism of FASL confers protection against female-specific cancers and those of FAS impact the cancers divergently.

Authors:  Sateesh Reddy Nallapalle; Sarika Daripally; V T S Vidudala Prasad
Journal:  Tumour Biol       Date:  2014-12-04

5.  Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.

Authors:  Prajitha Mohandas Edathara; Manjula Gorre; Sailaja Kagita; Sugunakar Vuree; Anuradha Cingeetham; Santhoshi Rani Nanchari; Phanni Bhushann Meka; Sandhya Annamaneni; Raghunadha Rao Digumarthi; Vishnupriya Satti
Journal:  Tumour Biol       Date:  2015-11-13

6.  Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients.

Authors:  Aziati Azwari Annuar; Ravindran Ankathil; Nazihah Mohd Yunus; Azlan Husin; Nur Shafawati Ab Rajab; Ahmad Aizat Abdul Aziz; Mohd Ismail Ibrahim; Sarina Sulong
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

7.  CD95 rs1800682A/G variant and tumor risk in Asians: evidence from a meta-analysis of 36 case-control studies containing 22,438 samples.

Authors:  Cheng Jin; Xiaomin Wu; Yuanlong Gu; Fenglai Yuan; Qinghai Ye; Feng Dai; Lijie Zhu; Yuanyuan Mi
Journal:  Med Sci Monit       Date:  2015-02-27

8.  FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.

Authors:  Lei Xu; Xin Zhou; Feng Jiang; Man-Tang Qiu; Zhi Zhang; Rong Yin; Lin Xu
Journal:  PLoS One       Date:  2013-09-23       Impact factor: 3.240

Review 9.  FAS-1377 G/A (rs2234767) polymorphism and cancer susceptibility: a meta-analysis of 17,858 cases and 24,311 controls.

Authors:  Zhou Zhong-Xing; Mi Yuan-Yuan; Ma Hai Zhen; Zou Jian-Gang; Zhang Li-Feng
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

Review 10.  Association of the polymorphisms in the Fas/FasL promoter regions with cancer susceptibility: a systematic review and meta-analysis of 52 studies.

Authors:  Yeqiong Xu; Bangshun He; Rui Li; Yuqin Pan; Tianyi Gao; Qiwen Deng; Huiling Sun; Guoqi Song; Shukui Wang
Journal:  PLoS One       Date:  2014-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.